Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Inclusion Criteria:

* Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease
* Tumor expression of melanocyte differentiation antigen (MDA: MART-1 = 2+ staining or \> 25%) by immunohistochemistry (IHC)
* Expression of human leukocyte antigen (HLA)-A201
* Zubrod performance status of '0-1' at the time of treatment
* Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic imaging (X-ray, computed tomography \[CT\] scan)
* Normal cardiac stress test will be required for all patients with any history of cardiac disease

Exclusion Criteria:

* Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entry
* Serum creatinine \> 1.6 mg/dL or Creatinine clearance \< 75 ml/min
* Serum glutamic oxaloacetic transaminase (SGOT) \> 150 IU or \> 3x upper limit of normal
* Bilirubin \> 1.6 mg/dL
* Prothrombin time \> 1.5 x control
* Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV1) \< 2.0 L or carbon monoxide diffusing capacity (DLco) (corr for hemoglobin \[Hgb\]) \< 75% will be excluded
* Congestive heart failure
* Clinically significant hypotension
* Symptoms of coronary artery disease
* Presence of cardiac arrhythmias on electrocardiograph (EKG) requiring drug therapy
* Ejection fraction \< 50 % (echocardiogram or multi gated acquisition scan \[MUGA\])
* Symptomatic central nervous system metastases greater than 1 cm at time of therapy; patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system (CNS) metastases without significant edema may be considered for treatment
* Patients with active infections or oral temperature \> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy
* Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy; (patients with bulky disease may undergo cytoreductive chemotherapy but treatment will be discontinued at least 3 weeks prior to T cell therapy)
* Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives
* Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy
* Current treatment with steroids
* Patients must not be receiving any other experimental drugs within 3 weeks of the initiation of the protocol and must have recovered from all side effects of such therapy
* Patients for whom we are unable to generate MART-1 specific T cells